Irinotecan plus oxaliplatin±G-CSF as second line therapy in patients with advanced 5-FU/leucovorin-refractory colorectal cancer (CC)

被引：0
|
作者：
Valencak, J
Lathan, B
Kornek, G
Raderer, M
Klein, G
Hejna, M
Brodovic, T
Weinländer, G
Depisch, D
Scheithauer, W
机构：
[1] Univ Vienna, Dept Int Med 1, Vienna, Austria
[2] Lathan Inst, Dortmund, Germany
[3] Wr Neustadt Gen Hosp, Neustadt, Germany
来源：
BRITISH JOURNAL OF CANCER | 1998年 / 78卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P47
引用
收藏
页码：36 / 36
页数：1
相关论文
共 50 条
  • [41] Oxaliplatin (LOHP) and 5-fluorouracil (5-FU) synergism in advanced colorectal cancer patients (ACRC)
    Meyer, V
    Delva, R
    Gamelin, E
    Lamezec, B
    Maillart, P
    DanquechinDorval, E
    Lortholary, A
    BoisdronCelle, M
    Maigre, M
    Brienza, S
    Cvitkovic, E
    Larra, F
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 746 - 746
  • [42] Oxaliplatin, 5-FU and folinic acid (OFFA) as II-line chemotherapy in advanced colorectal cancer
    Tassinari, D
    Panzini, I
    Pasquini, E
    Desiderio, F
    Drudi, G
    Fattori, PP
    Gianni, L
    Oliveno, G
    Tononi, A
    Ravaioli, A
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S80 - S80
  • [43] Cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure of irinotecan, oxaliplatin and 5-fluorouracil
    Pfeiffer, Per
    Nielsen, Dorte
    Yilmaz, Mette
    Iversen, Anja
    Vejlo, Christian
    Jensen, Benny Vittrup
    ACTA ONCOLOGICA, 2007, 46 (05) : 697 - 701
  • [44] Weekly irinotecan plus UFT and leucovorin as first-line chemotherapy of patients with advanced colorectal cancer
    M. Méndez
    P. G. Alfonso
    E. Pujol
    E. González
    C. Castañon
    P. Cerezuela
    Y. López-Mateos
    J. J. Cruz
    Investigational New Drugs, 2005, 23 : 243 - 251
  • [45] Weekly irinotecan plus UFT and leucovorin as first-line chemotherapy of patients with advanced colorectal cancer
    Méndez, M
    Alfonso, PG
    Pujol, E
    González, E
    Castañon, C
    Cerezuela, P
    López-Mateos, Y
    Cruz, JJ
    INVESTIGATIONAL NEW DRUGS, 2005, 23 (03) : 243 - 251
  • [46] Dose escalating study of 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) and cetuximab in first-line therapy of patients with metastatic colorectal cancer
    Trarbach, T.
    Schuette, K.
    Stoehlmacher, J.
    Goekkurt, E.
    Guenther, H.
    Ubbelohde, U.
    Stroszczynski, C.
    Ehninger, G.
    Folprecht, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [47] Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer
    Graziano, Francesco
    Ruzzo, Annamaria
    Loupakis, Fotios
    Canestrari, Emanuele
    Santini, Daniele
    Catalano, Vincenzo
    Bisonni, Renato
    Torresi, Umberto
    Floriani, Irene
    Schiavon, Gaia
    Andreoni, Francesca
    Maltese, Paolo
    Rulli, Eliana
    Humar, Bostjan
    Falcone, Alfredo
    Giustini, Lucio
    Tonini, Giuseppe
    Fontana, Andrea
    Masi, Gianluca
    Magnani, Mauro
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (09) : 1427 - 1434
  • [48] Bevacizumab plus infusional 5-fluorouracil,leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy:A pilot study
    Hyuk-Chan Kwon
    Sung Yong Oh
    Suee Lee
    Sung-Hyun Kim
    Hyo-Jin Kim
    World Journal of Gastroenterology, 2007, (46) : 6231 - 6235
  • [49] Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: A pilot study
    Kwon, Hyuk-Chan
    Oh, Sung Yong
    Lee, Suee
    Kim, Sung-Hyun
    Kim, Hyo-Jin
    WORLD JOURNAL OF GASTROENTEROLOGY, 2007, 13 (46) : 6231 - 6235
  • [50] Metronomic therapy with 5-FU, weekly nab-paclitaxel, leucovorin, and oxaliplatin, plus bevacizumab for advanced pancreatic cancer: A phase II study.
    Isacoff, William H.
    Reber, Howard A.
    Hines, Oscar J.
    Donahue, Timothy R.
    Purcell, Fay M.
    Clerkin, Barbara M.
    Clerkin, Kara M.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345